Comparison
DSIP vs. Linaclotid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
62568-57-4
851199-59-2
Molecular weight
848.81 g/mol
1526.74 g/mol
Half-life
0.1 h
no data
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Gluno data
Mechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Linaclotid
Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
0
of which in humans
1
0
Effects recorded
3
2
Open conflicts
1
0
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between DSIP and Linaclotid?
- DSIP is classified as "Research other", while Linaclotid is classified as "Research other". DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, DSIP or Linaclotid?
- The highest available evidence level is "Human trial" for DSIP and "Human RCT" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of DSIP and Linaclotid in Germany and the United States?
- Germany: DSIP — Unapproved, Linaclotid — Prescription. United States: DSIP — Unapproved, Linaclotid — Prescription. These are factual summaries with source and review date on the individual pages.